Aeterna Zentaris (AEZS) |
|
0.3571 0.007 (2.03%)
|
10-23 23:40 |
|
Open: |
0.3542 |
Pre. Close: |
0.35 |
|
High:
|
0.363 |
Low:
|
0.3456 |
|
Volume:
|
520,074 |
Market Cap:
|
22M |
|
|
|
|
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company is headquartered in Montreal, Quebec and currently employs 22 full-time employees. The firm operates through the biopharmaceutical segment. The firm is engaged in drug development activities and in the promotion of products for others. The firm's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The firm focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The firm's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.361 - 0.363 |
0.363 - 0.364 |
|
Low:
|
0.345 - 0.347 |
0.347 - 0.35 |
|
Close:
|
0.356 - 0.36 |
0.36 - 0.364 |
|
Technical analysis |
as of: 2020-10-23 4:40:17 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.44 One year: 0.48 |
| Support: |
Support1: 0.33 Support2: 0.27 |
| Resistance: |
Resistance1: 0.38 Resistance2: 0.41 |
| Pivot: |
0.37  |
| Moving Average: |
MA(5): 0.36 MA(20): 0.37
MA(100): 0.53 MA(250): 0.76 |
| MACD: |
MACD(12,26): -0.01 Signal(9): -0.01 |
| Stochastic oscillator: |
%K(14,3): 26.17 %D(3): 29.09 |
| RSI: |
RSI(14): 42.89 |
| 52-week: |
High: 1.54 Low: 0.33 Change(%): -64.6 |
| Average Vol(K): |
3-Month: 321069 10-Days: 80353 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.AEZS has closed above bottom band by 23.6%. Bollinger Bands are 80.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to AEZS's normal range. The bands have been in this narrow range for 66 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 22 Oct 2020
Aeterna Zentaris Inc. (AEZS): Significant Improvements, Worth Considering - Stocks Register
Thu, 22 Oct 2020
We Analyzed the Future Direction of Aeterna Zentaris Inc. (AEZS), Here is What We Found - The News Heater
Fri, 09 Oct 2020
The Rosen Law Firm, PA and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc. - AEZS - PRNewswire
Fri, 09 Oct 2020
Aeterna Zentaris Inc. [AEZS] Revenue clocked in at $1.50 million, down -58.65% YTD: What’s Next? - The DBT News
Thu, 08 Oct 2020
Aeterna Zentaris Inc. (AEZS) last month performance of -1.34% certainly makes it a sizzling prospect - News Daemon
Thu, 08 Oct 2020
Riding the Trend or Protecting Profits | Aeterna Zentaris Inc. (AEZS) - The News Heater
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
63 |
| Shares Float (M) |
24 |
|
% Held by Insiders
|
0.03 |
|
% Held by Institutions
|
10.82 |
|
Shares Short (K)
|
1,820 |
|
Shares Short P. Month (K)
|
1,700 |
Stock Financials |
|
EPS
|
-0.205 |
|
EPS Est This Year
|
-1.020 |
|
EPS Est Next Year
|
-0.290 |
|
Book Value (p.s.)
|
0.040 |
|
Profit Margin
|
-274.71 |
|
Operating Margin
|
-490.20 |
|
Return on Assets (ttm)
|
-23.3 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
-64.9 |
|
Gross Profit (p.s.)
|
0.002 |
|
Sales Per Share
|
0.023 |
|
EBITDA (p.s.)
|
-0.114 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-10 |
|
Levered Free Cash Flow (M)
|
-7 |
Stock Valuations |
|
PE Ratio
|
-1.74 |
|
PEG Ratio
|
|
|
Price to Book value
|
8.93 |
|
Price to Sales
|
15.33 |
|
Price to Cash Flow
|
-2.15 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
